Eloralintide is one of the most closely watched drugs in Eli Lilly's obesity pipeline, and it works through a mechanism distinct from the company's blockbuster GLP-1/GIP drug tirzepatide. This guide covers what eloralintide is, how it's designed to work, and exactly where it stands in the drug development process.

What It Is

Eloralintide is an investigational, injectable peptide drug that Lilly describes as a selective, long-acting amylin receptor agonist. It is engineered to activate amylin receptors while minimizing activity at other related receptors, distinguishing it from dual or “co-agonist” amylin drugs like Novo Nordisk's cagrilintide. Amylin is a hormone naturally co-secreted with insulin by the pancreas that promotes feelings of fullness and slows gastric emptying through signaling pathways in the brain that are separate from, but complementary to, the GLP-1 pathway that drugs like semaglutide and tirzepatide target.

How It Differs From GLP-1 Drugs

Because eloralintide works on amylin receptors rather than GLP-1 receptors, it is being studied both as a potential standalone obesity treatment and as an add-on to GLP-1/GIP drugs like tirzepatide, on the theory that combining complementary appetite pathways could produce greater weight loss than either mechanism alone. Lilly has described eloralintide as a candidate for use “as a complementary treatment to incretin therapy,” and has run dedicated combination trials pairing it with tirzepatide under the name EloraTZP, discussed in this site's news coverage of that program's most recent results.

Regulatory Status

Eloralintide is not FDA-approved for any use. It has completed Phase 1 and Phase 2 clinical testing, both as a standalone drug and in combination with tirzepatide. Lilly has said it plans to begin Phase 3 trials for the combination program in the fourth quarter of 2026, and Phase 3 monotherapy studies were slated to begin around the end of 2025. Reaching Phase 3 is a meaningful milestone, but the drug remains years away from any possible FDA decision, and most drug candidates that enter Phase 3 still do not ultimately win approval.

What the Trials Have Shown So Far

In an earlier Phase 2 monotherapy trial in adults with obesity or overweight, eloralintide alone produced up to 20.1% weight loss, which Lilly described as “meaningful weight loss” with “favorable tolerability.” In combination with tirzepatide, results have moved in stages: an initial 16-week Phase 2 study showed the combination reaching 17% weight loss, and a longer, more recent 48-week Phase 2b trial reported weight loss of up to 23.3% at the highest combination dose, compared with 14.8% for tirzepatide alone over the same period. As with any amylin- or incretin-pathway drug, gastrointestinal side effects such as nausea, diarrhea, and vomiting have been the most commonly reported adverse events across these trials.

How It Fits Into the Broader Amylin Drug Race

Eloralintide is one of several amylin-pathway candidates in active development alongside Novo Nordisk's cagrilintide (paired with semaglutide as CagriSema) and Zealand Pharma and Roche's petrelintide, both covered elsewhere on this site. Each company is testing a somewhat different engineering approach to the amylin receptor, and head-to-head comparisons between these candidates don't yet exist, so it's not currently possible to say which approach will ultimately prove most effective or best tolerated in a real-world patient population.

The Bottom Line

Eloralintide is a genuinely novel mechanism with encouraging early trial results, but it is still an experimental, unapproved drug being tested in a limited number of clinical trial participants. Phase 2 and Phase 2b results, while promising, are not a guarantee of eventual FDA approval or that the effects and side-effect profile seen so far will hold up in larger, longer Phase 3 trials. Anyone interested in currently available obesity treatments should discuss FDA-approved options with a licensed physician rather than waiting on, or attempting to source, an investigational compound that is not legally available outside of clinical trials.